Organization
Corvus Pharmaceuticals
4 clinical trials
Clinical trial
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects With Relapsed/Refractory T-Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2026-04-30
Clinical trial
A Phase 1, Randomized, Blinded, Placebo-controlled, Dose Escalation Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of ITK Inhibitor Soquelitinib in Participants With Moderate to Severe Atopic DermatitisStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase 3, Randomized, Placebo Controlled, Double-blind, Multicenter, Stratified Study of CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 PatientsStatus: Terminated, Estimated PCD: 2021-08-18